12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
Finasteride may lower allopregnanolone levels, potentially affecting mood, but many users report improved mental health due to reduced hair loss. Experiences with finasteride and dutasteride vary, with some experiencing side effects and others finding them beneficial for hair retention and overall happiness.
Hair loss affects self-esteem and mental health, with treatments like finasteride and minoxidil commonly used. People feel misunderstood by those without hair loss and seek more empathy and better treatment options.
Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.
The user experienced significant hair regrowth after using minoxidil for 9 months and finasteride for 3 months, with plans to continue treatment and possibly get a hair transplant. Some users suggested adding microneedling and other treatments, while others discussed potential side effects of finasteride.
The conversation discusses the effectiveness of AMSbzs supplements in significantly increasing hair count, weight, and keratin content. The user questions why this treatment isn't more widely known despite its impressive results.
A user switched from 2% to 5% minoxidil, alongside using finasteride and dermarolling, to address hair thinning and is curious about potential shedding. They have not experienced noticeable hair loss or shedding since starting the treatment.
Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.
A new stem cell therapy shows promise in treating hair loss, but skepticism remains about its availability. Users humorously discuss the effectiveness of treatments on mice compared to humans.
Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
The user experienced increased hair shedding after switching to a new treatment with higher doses of finasteride (0.3%), minoxidil (7%), ketoconazole (2.2%), and biotin (0.2%). They are curious about the shedding but not concerned about noticeable thinning.
Hair loss treatments, specifically, discussing the effectiveness and side effects of finasteride, minoxidil, and RU58841 in various microdoses. It also includes an updated graph which provides information on how different doses affect DHT levels, scalp skin and serum androgen levels, as well as hair count.
A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.
The user is using oral minoxidil, finasteride, and biotin for hair loss, with positive results after two months. They have also improved their diet and exercise routine, and report no side effects from the medication.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
The conversation discusses using topical liposomal finasteride for hair loss, with concerns about high DHT levels. The user's DHT level is above the normal range, which may affect hair health.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
Concerns about metal particles from dermapen or dermaroller needles potentially entering the skin and lymph nodes, similar to tattoo needles. Discussion includes the possibility of using Minoxidil, finasteride, and RU58841 for hair loss treatment.
The user shared progress pictures after 80 days on oral minoxidil, noting improvement despite some shedding and no side effects. The discussion included comparisons between oral and topical minoxidil, with some users preferring oral for convenience and effectiveness.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
An 18-year-old male with hair loss is considering starting finasteride but is concerned about potential side effects like gynecomastia due to his prolactin levels. He seeks guidance on whether his bloodwork indicates it's safe to begin treatment.
Microneedling with 5% minoxidil improves hair growth for hair loss patients. Best protocol: 1.5mm dermaroller weekly for 12 weeks or 0.6mm dermapen every 2 weeks for 12 weeks, skipping topicals for 24 hours.
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.
The conversation discusses whether dutasteride might cause less depression than finasteride for hair loss treatment, with some users suggesting it could due to different mechanisms of action or molecular size, while others express skepticism or share personal experiences with these medications.
Finasteride increased the user's estrogen levels by 51%, causing concerns about gynecomastia and sleep issues. Despite potential side effects, the user prefers continuing finasteride to prevent hair loss, considering it essential for self-esteem.
Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.
Nutrafol, a hair loss supplement, has limited and potentially biased research, with one study showing a 10% increase in hair count for women after 6 months but no significant results for men. The user concludes that cheaper, well-studied options like minoxidil may be more effective, especially for men, given the lack of evidence supporting Nutrafol.
A user who underwent exosomes treatment for hair loss and reported their experience, with other users discussing the procedure and offering advice. They discussed options such as finasteride, minoxidil, RU58841 and hair transplants.
Microneedling before applying topical finasteride or dutasteride may enhance their effectiveness by increasing local absorption in the scalp, despite concerns about systemic absorption. Users discuss combining this method with oral treatments and minoxidil, noting potential benefits and side effects.